Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach

The Euro Heart Survey on Atrial Fibrillation


      Contemporary clinical risk stratification schemata for predicting stroke and thromboembolism (TE) in patients with atrial fibrillation (AF) are largely derived from risk factors identified from trial cohorts. Thus, many potential risk factors have not been included.


      We refined the 2006 Birmingham/National Institute for Health and Clinical Excellence (NICE) stroke risk stratification schema into a risk factor-based approach by reclassifying and/or incorporating additional new risk factors where relevant. This schema was then compared with existing stroke risk stratification schema in a real-world cohort of patients with AF (n = 1,084) from the Euro Heart Survey for AF.


      Risk categorization differed widely between the different schemes compared. Patients classified as high risk ranged from 10.2% with the Framingham schema to 75.7% with the Birmingham 2009 schema. The classic CHADS2 (Congestive heart failure, Hypertension, Age > 75, Diabetes, prior Stroke/transient ischemic attack) schema categorized the largest proportion (61.9%) into the intermediate-risk strata, whereas the Birmingham 2009 schema classified 15.1% into this category. The Birmingham 2009 schema classified only 9.2% as low risk, whereas the Framingham scheme categorized 48.3% as low risk. Calculated C-statistics suggested modest predictive value of all schema for TE. The Birmingham 2009 schema fared marginally better (C-statistic, 0.606) than CHADS2. However, those classified as low risk by the Birmingham 2009 and NICE schema were truly low risk with no TE events recorded, whereas TE events occurred in 1.4% of low-risk CHADS2 subjects. When expressed as a scoring system, the Birmingham 2009 schema (CHA2DS2-VASc acronym) showed an increase in TE rate with increasing scores (P value for trend = .003).


      Our novel, simple stroke risk stratification schema, based on a risk factor approach, provides some improvement in predictive value for TE over the CHADS2 schema, with low event rates in low-risk subjects and the classification of only a small proportion of subjects into the intermediate-risk category. This schema could improve our approach to stroke risk stratification in patients with AF.
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lip GY
        • Lim HS
        Atrial fibrillation and stroke prevention.
        Lancet Neurol. 2007; 6: 981-993
        • Mant J
        • Hobbs FD
        • Fletcher K
        • BAFTA investigators
        • Midland Research Practices Network (MidReC)
        • et al.
        Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.
        Lancet. 2007; 370: 493-503
        • Sato H
        • Ishikawa K
        • Kitabatake A
        • Japan Atrial Fibrillation Stroke Trial Group
        • et al.
        Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial.
        Stroke. 2006; 37: 447-451
        • Stroke Risk in Atrial Fibrillation Working Group
        Independent predictors of stroke in patients with atrial fibrillation: a systematic review.
        Neurology. 2007; 69: 546-554
        • Stroke Risk in Atrial Fibrillation Working Group
        Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation.
        Stroke. 2008; 39: 1901-1910
        • Baruch L
        • Gage BF
        • Horrow J
        • et al.
        Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?.
        Stroke. 2007; 38: 2459-2463
        • Poli D
        • Antonucci E
        • Grifoni E
        • Abbate R
        • Gensini GF
        • Prisco D
        Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention.
        Thromb Haemost. 2009; 101: 367-372
        • Lip GY
        • Lane D
        • Van Walraven C
        • Hart RG
        Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation.
        Stroke. 2006; 37: 2294-2300
        • Fang MC
        • Go AS
        • Chang Y
        • Borowsky L
        • Pomernacki NK
        • Singer DE
        • ATRIA Study Group
        Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation.
        J Am Coll Cardiol. 2008; 51: 810-815
        • Singer DE
        • Albers GW
        • Dalen JE
        • American College of Chest Physicians
        • et al.
        Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition).
        Chest. 2008; 133: 546S-592S
        • Fuster V
        • Rydén LE
        • Cannom DS
        • Task Force on Practice Guidelines, American College of Cardiology/American Heart Association
        • Committee for Practice Guidelines, European Society of Cardiology
        • European Heart Rhythm Association
        • Heart Rhythm Society
        • et al.
        ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation).
        Eur Heart J. 2006; 27: 1979-2030
        • National Collaborating Centre for Chronic Conditions
        Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. Royal College of Physicians, London2006
        • Dagres N
        • Nieuwlaat R
        • Vardas PE
        • et al.
        Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation.
        J Am Coll Cardiol. 2007; 49: 572-577
        • Fang MC
        • Singer DE
        • Chang Y
        • et al.
        Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study.
        Circulation. 2005; 112: 1687-1691
        • Lane DA
        • Lip GYH
        Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients.
        Thromb Haemost. 2009; 101: 802-805
        • Schmitt J
        • Duray G
        • Gersh BJ
        • Hohnloser SH
        Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications.
        Eur Heart J. 2009; 30: 1038-1045
        • Conway DS
        • Lip GY
        Comparison of outcomes of patients with symptomatic peripheral artery disease with and without atrial fibrillation (the West Birmingham Atrial Fibrillation Project).
        Am J Cardiol. 2004; 93 (A10): 1422-1425
        • Siu CW
        • Jim MH
        • Ho HH
        • et al.
        Transient atrial fibrillation complicating acute inferior myocardial infarction: implications for future risk of ischemic stroke.
        Chest. 2007; 132: 44-49
        • Lip GYH
        Coronary artery disease and ischemic stroke in atrial fibrillation.
        Chest. 2007; 132: 8-10
        • The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography
        Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation.
        Ann Intern Med. 1998; 128: 639-647
        • Nieuwlaat R
        • Prins MH
        • Le Heuzey JY
        • et al.
        Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation.
        Eur Heart J. 2008; 29: 1181-1189
        • Nieuwlaat R
        • Capucci A
        • Lip GY
        • Euro Heart Survey Investigators
        • et al.
        Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation.
        Eur Heart J. 2006; 27: 3018-3026
        • Hart R
        • Pearce L
        • McBride R
        • Rothbart R
        • Asinger R
        Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials.
        Stroke. 1999; 30: 1223-1229
        • Atrial Fibrillation Investigators
        Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation analysis of pooled data from five randomised clinical trials.
        Arch Intern Med. 1994; 154: 1449-1457
        • Wang TJ
        • Massaro JM
        • Levy D
        • et al.
        A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study.
        JAMA. 2003; 290: 1049-1056
        • Gage BF
        • van Walraven C
        • Pearce L
        • et al.
        Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.
        Circulation. 2004; 110: 2287-2292
        • van Walraven C
        • Hart RG
        • Connolly S
        • et al.
        Effect of age on stroke prevention therapy in patients with atrial fibrillation. The Atrial Fibrillation Investigators.
        Stroke. 2009; 40: 1410-1416
        • Hart RG
        • Pearce LA
        • Aguilar MI
        Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.
        Ann Intern Med. 2007; 146: 857-867
        • Nieuwlaat R
        • Olsson SB
        • Lip GY
        • Euro Heart Survey Investigators
        • The Euro Heart Survey on Atrial Fibrillation
        • et al.
        Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation.
        Am Heart J. 2007; 153: 1006-1012
        • Stroke Prevention in Atrial Fibrillation investigators
        A differential effect of aspirin in prevention of stroke on atrial fibrillation.
        J Stroke Cerebrovasc Dis. 1993; 3: 181-188
        • Antithrombotic Trialists' Collaboration
        Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
        BMJ. 2002; 324: 71-86
        • Belch J
        • MacCuish A
        • Campbell I
        • Prevention of Progression of Arterial Disease and Diabetes Study Group
        Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.
        BMJ. 2008; 337: a1840
        • Ogawa H
        • Nakayama M
        • Morimoto T
        • Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators
        • et al.
        Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
        JAMA. 2008; 300: 2134-2141
        • Connolly SJ
        • Pogue J
        • Eikelboom J
        • ACTIVE W Investigators
        • et al.
        Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.
        Circulation. 2008; 118: 2029-2037